TCR cell therapies vanquish solid tumors — finally
IF 33.1
1区 生物学
Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
引用次数: 0
Abstract
The FDA’s approval of the first genetically modified T cell therapy for treating a rare sarcoma is paving the way for next-generation therapies that tackle other types of solid tumors.
TCR 细胞疗法终于战胜了实体瘤
美国食品和药物管理局（FDA）批准了首个用于治疗一种罕见肉瘤的转基因 T 细胞疗法，这为治疗其他类型实体瘤的下一代疗法铺平了道路。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
Nature biotechnology
工程技术-生物工程与应用微生物
CiteScore
63.00
自引率
1.70%
发文量
382
审稿时长
3 months
期刊介绍：
Nature Biotechnology is a monthly journal that focuses on the science and business of biotechnology. It covers a wide range of topics including technology/methodology advancements in the biological, biomedical, agricultural, and environmental sciences. The journal also explores the commercial, political, ethical, legal, and societal aspects of this research.
The journal serves researchers by providing peer-reviewed research papers in the field of biotechnology. It also serves the business community by delivering news about research developments. This approach ensures that both the scientific and business communities are well-informed and able to stay up-to-date on the latest advancements and opportunities in the field.
Some key areas of interest in which the journal actively seeks research papers include molecular engineering of nucleic acids and proteins, molecular therapy, large-scale biology, computational biology, regenerative medicine, imaging technology, analytical biotechnology, applied immunology, food and agricultural biotechnology, and environmental biotechnology.
In summary, Nature Biotechnology is a comprehensive journal that covers both the scientific and business aspects of biotechnology. It strives to provide researchers with valuable research papers and news while also delivering important scientific advancements to the business community.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
